PMID- 38247364
OWN - NLM
STAT- MEDLINE
DCOM- 20240123
LR  - 20240131
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 35
IP  - 1
DP  - 2024 Dec
TI  - The efficacy and safety of low-dose rituximab in the treatment of pemphigus 
      vulgaris: a cohort study.
PG  - 2302071
LID - 10.1080/09546634.2024.2302071 [doi]
AB  - BACKGROUND: Rituximab (RTX) is considered the first-line treatment for pemphigus 
      vulgaris (PV), which is a B-cell-mediated acquired autoimmune disease. However, 
      no consensus on the optimum dosage has been achieved. OBJECTIVES: To investigate 
      the efficacy and safety of low-dose RTX (a single infusion of 500 mg) for the 
      treatment of PV, a cohort study was conducted for patients with PV, along with a 
      12-month follow-up following the administration of RTX. METHODS: Patients with 
      moderate or severe PV were divided into group A (low-dose RTX combined with 
      corticosteroids) and group B (corticosteroids alone). Data on complete remission 
      (CR) rates, doses of corticosteroids, cumulative doses of corticosteroids at the 
      third, sixth, and twelfth months, pemphigus disease area index and adverse 
      effects (AEs) were collected. RESULTS: Forty-four patients with moderate or 
      severe PV were enrolled in this study (19 in group A and 25 in group B). Patients 
      treated with low-dose RTX had higher CR rates, lower doses of corticosteroids at 
      the third, sixth, and twelfth months, lower cumulative doses of corticosteroids 
      at the sixth and twelfth months, and fewer AEs than those who received 
      corticosteroids alone. CONCLUSIONS: This study indicated that low-dose RTX may be 
      a beneficial and secure therapy option for patients with moderate to severe PV.
FAU - Zhou, Xingli
AU  - Zhou X
AD  - Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, 
      Frontiers Science Center for Disease-related Molecular Network, West China 
      Hospital, Sichuan University, Chengdu, China.
FAU - Zhan, Tongying
AU  - Zhan T
AD  - West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 
      China.
AD  - Department of Dermatology, Women's and Children's Hospital Affiliated to Medical, 
      College of Chengdu University of Electronic Science and Technology/Chengdu, 
      Women's and Children's Central Hospital, Chengdu, China.
FAU - Xu, Xiaoxi
AU  - Xu X
AD  - Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Lan, Tianjiao
AU  - Lan T
AD  - West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 
      China.
AD  - West China School of Public Health and West China Fourth Hospital, Sichuan 
      University, Chengdu, China.
FAU - Hu, Hongxiang
AU  - Hu H
AD  - Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, 
      Frontiers Science Center for Disease-related Molecular Network, West China 
      Hospital, Sichuan University, Chengdu, China.
FAU - Zhou, Yuxi
AU  - Zhou Y
AD  - Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, 
      Frontiers Science Center for Disease-related Molecular Network, West China 
      Hospital, Sichuan University, Chengdu, China.
FAU - Xia, Dengmei
AU  - Xia D
AD  - West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Wang, Jinqiu
AU  - Wang J
AD  - Department of Outpatient, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Wang, Yiyi
AU  - Wang Y
AD  - Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, 
      Frontiers Science Center for Disease-related Molecular Network, West China 
      Hospital, Sichuan University, Chengdu, China.
FAU - Xiao, Yue
AU  - Xiao Y
AD  - Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, 
      Frontiers Science Center for Disease-related Molecular Network, West China 
      Hospital, Sichuan University, Chengdu, China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, 
      Frontiers Science Center for Disease-related Molecular Network, West China 
      Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20240122
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 0 (Adrenal Cortex Hormones)
SB  - IM
MH  - Humans
MH  - *Pemphigus/drug therapy
MH  - Cohort Studies
MH  - Rituximab/adverse effects
MH  - *Autoimmune Diseases
MH  - Pathologic Complete Response
MH  - Adrenal Cortex Hormones
OTO - NOTNLM
OT  - Pemphigus vulgaris
OT  - adverse events
OT  - corticosteroids
OT  - low-dose
OT  - rituximab
EDAT- 2024/01/22 06:42
MHDA- 2024/01/23 06:42
CRDT- 2024/01/22 03:33
PHST- 2024/01/23 06:42 [medline]
PHST- 2024/01/22 06:42 [pubmed]
PHST- 2024/01/22 03:33 [entrez]
AID - 10.1080/09546634.2024.2302071 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2024 Dec;35(1):2302071. doi: 10.1080/09546634.2024.2302071. 
      Epub 2024 Jan 22.